Pier Woudstra
YOU?
Author Swipe
View article: Safety, Feasibility, and Diagnostic Yield of Invasive Coronary Function Testing
Safety, Feasibility, and Diagnostic Yield of Invasive Coronary Function Testing Open
Importance Patients with angina and no obstructive coronary artery disease frequently have coronary vasomotor dysfunction as underlying pathophysiological mechanism, comprising epicardial spasm, microvascular spasm, and/or microcirculatory…
View article: Angina Severity and Symptom Improvement Are Associated With Diagnostic Acetylcholine Provocation Dose in Vasospastic Angina
Angina Severity and Symptom Improvement Are Associated With Diagnostic Acetylcholine Provocation Dose in Vasospastic Angina Open
Background A coronary function test (CFT) is the recommended diagnostic test to identify coronary vasomotor dysfunction as a cause of symptoms in patients with angina and nonobstructive coronary arteries (ANOCA). Acetylcholine is the commo…
View article: Safety and feasibility of nationwide invasive coronary function testing in patients with angina and no obstructive coronary artery disease (NL-CFT)
Safety and feasibility of nationwide invasive coronary function testing in patients with angina and no obstructive coronary artery disease (NL-CFT) Open
Background and purpose Patients with angina and no obstructive coronary artery disease (ANOCA) frequently have coronary vasomotor dysfunction (CVDys) as underlying pathophysiological mechanism, comprising epicardial spasm, microvascular sp…
View article: 2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation
2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation Open
Recently, the European Society of Cardiology (ESC) has updated its guidelines for the management of patients with acute coronary syndrome (ACS) without ST-segment elevation. The current consensus document of the Dutch ACS working group and…
View article: Final five‐year results of the <scp>REMEDEE</scp> Registry: Real‐world experience with the dual‐therapy <scp>COMBO</scp> stent
Final five‐year results of the <span>REMEDEE</span> Registry: Real‐world experience with the dual‐therapy <span>COMBO</span> stent Open
Objectives This final report from the REMEDEE Registry assessed the long‐term safety and efficacy of the dual‐therapy COMBO stent in a large unselected patient population. Background The bio‐engineered COMBO stent (OrbusNeich Medical BV, T…
View article: Ten-year outcomes of an early invasive or a selective invasive strategy in non-ST-segment elevation acute coronary syndrome patients with and without diabetes mellitus: a subgroup analysis of the ICTUS trial
Ten-year outcomes of an early invasive or a selective invasive strategy in non-ST-segment elevation acute coronary syndrome patients with and without diabetes mellitus: a subgroup analysis of the ICTUS trial Open
Contains fulltext : 220845.pdf (Publisher’s version ) (Open Access)
View article: Coronary artery disease and new stent technology
Coronary artery disease and new stent technology Open
Coronary artery disease is a pathophysiological process that affects a large number of patients and remains one of the leading causes of mortality up until day. In this thesis we did investigate the natural course of atherosclerosis in a p…
View article: P1664Clinical outcomes by potency of P2Y12 inhibitor following COMBO DTS PCI: From the COMBO collaboration
P1664Clinical outcomes by potency of P2Y12 inhibitor following COMBO DTS PCI: From the COMBO collaboration Open
Coronary interventions: stents 331pared with non-TGCV, resulting higher binary restenosis rate was observed in TGCV.TGCV was an independent predictor for in-stent late loss in multiple linear regression analysis.Baseline characteristics an…
View article: P1661Evaluation of transradial versus transfemoral procedures in all-comers patients treated with the dual-therapy stent
P1661Evaluation of transradial versus transfemoral procedures in all-comers patients treated with the dual-therapy stent Open
lar in group III (9,12±2,65 mg/l la 11,91±1,81 mg/l), reflected by encreasing the hs-CRP level (p<0.05).Conclusions: Patients with a stent length ≥30 mm versus those with a shorter stent (≤15 mm) already had a higher level of both pro-oxid…
View article: Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis
Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis Open
In a propensity-matched analysis, the COMBO stent showed similar rates of TLF and ST at two-year follow-up compared to Resolute Integrity and PROMUS Element.
View article: Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry
Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry Open
Objective The dual-therapy stent combines an abluminal biodegradable drug-eluting coating, with a ‘pro-healing’ luminal layer. This bioengineered layer attracts circulating endothelial progenitor cells that can differentiate into normal en…